Quick View
| Metric | Current Period | Same Period Previous Year | YoY |
|---|---|---|---|
| Revenue | ¥10.73B | ¥10.20B | +5.2% |
| Operating Income | ¥0.67B | ¥0.80B | −16.7% |
| Ordinary Income | ¥0.64B | ¥0.81B | −21.3% |
| Net Income | ¥0.45B | ¥0.60B | −25.8% |
| ROE | 1.0% | 1.4% | - |
Executive Summary
The Company posted higher revenue but lower profit in Q1 due to deterioration in the gross profit margin, with top-line growth offset by reduced profitability. Revenue increased to ¥10.73B (¥10.20B in the same period of the previous year, +5.2% YoY), while Operating Income fell to ¥0.667B (¥0.800B, -16.7%), Ordinary Income to ¥0.640B (¥0.813B, -21.3%), and Net Income attributable to owners of the parent to ¥0.445B (¥0.600B, -25.8%), resulting in double-digit declines across all major profit indicators. The primary factor was the decline in the gross profit margin to 38.0% from 40.2% in the previous year, meaning that the deterioration in gross profit could not be fully absorbed despite SG&A expenses being contained to a +3.3% increase.
Factors Affecting Financial Performance
【Revenue】Revenue increased to ¥10.73B, representing a +5.2% YoY increase. The Company operates as a single segment, the Testing Reagents Business, and detailed factors behind changes by business are not disclosed; however, revenue continues to trend upward due to volume, pricing, or a combination of both.
【Profit and Loss】Gross profit was ¥4.08B, a slight decrease from ¥4.099B? to ¥4.077B in the previous year, and the gross profit margin declined to 38.0% from 40.2%, a decrease of 2.2pt. SG&A expenses were ¥3.41B (¥3.30B in the previous year, +3.3%), increasing at a slower pace than revenue (+5.2%); however, the impact of the deterioration in the gross profit margin outweighed this factor, and Operating Income declined to ¥0.667B (-16.7%). Non-operating income and expenses shifted from net income of ¥0.013B in the previous year to net expenses of ¥0.026B in the current period. The increase in interest expenses to ¥0.019B (¥0.004B in the previous year) was a significant factor, resulting in Ordinary Income of ¥0.640B (-21.3%). Extraordinary income and expenses were virtually zero, and the impact of temporary factors was limited. The effective tax rate increased to 30.5% from 26.3% in the previous year, and Net Income was ¥0.445B (-25.8%). Revenue increased, but profit declined.
Key Financial Indicators
【Profitability】The Operating Income margin was 6.2%, down 1.6pt from 7.8% in the previous year, while the Net Income margin also declined to 4.1% (5.9% in the previous year). ROE was 1.0%, primarily due to the deterioration in the Net Income margin.【Cash Flow Quality】Comprehensive income was ¥0.419B, slightly below Net Income of ¥0.445B. Factors contributing to the divergence included adjustments related to retirement benefits of △¥0.016B and valuation differences on securities of △¥0.010B.【Investment Efficiency】Against total assets of ¥61.90B, Net Income was ¥0.445B. Basic EPS was ¥13.52 (¥18.21 in the previous year), while BPS was ¥1,316.79 (¥1,333.07 in the previous year), both showing slight declines.【Financial Soundness】The Equity Ratio was 70.3% (70.1% in the previous year), remaining virtually flat at a high level. Short-term liquidity was favorable, with a current ratio of 219.5% and a quick ratio of 190.4%. Interest coverage was 35.1x (EBIT of ¥0.667B / interest expenses of ¥0.019B), indicating a high capacity to withstand interest payment burdens.
Cash Flow Analysis
As no statement of cash flows has been disclosed, funding trends are assessed based on changes in the balance sheet. Cash and deposits were ¥9.89B, down 9.6% from ¥10.94B in the previous year, likely reflecting cash outflows associated with corporate tax payments and bonus payments. In fact, income taxes payable declined by ¥0.468B, from ¥0.708B in the previous year to ¥0.240B, while the provision for bonuses declined by ¥0.334B, from ¥0.693B to ¥0.359B. Both are considered to reflect balance reductions resulting from seasonal payments. Meanwhile, accounts payable increased to ¥5.23B (¥4.84B in the previous year, +8.1%), suggesting an increase in procurement activity or changes in payment terms. Inventories were ¥4.21B (¥4.35B in the previous year), showing a slight decline, while accounts receivable were ¥10.35B (¥10.17B in the previous year), remaining virtually flat. Construction in progress declined substantially from ¥0.767B in the previous year to ¥0.226B, indicating the completion of capital investment or progress in recognizing assets on the balance sheet.
Earnings Quality
Non-operating income and expenses shifted from net income of ¥0.013B in the previous year to net expenses of ¥0.026B in the current period, primarily due to the increase in interest expenses (¥0.004B → ¥0.019B). Although the Company recorded foreign exchange gains of ¥0.011B, the amount was small and had a limited impact on Ordinary Income. Extraordinary income and expenses were virtually nonexistent, consisting solely of extraordinary losses of ¥0.0B. Accordingly, temporary factors had an extremely limited impact on earnings, and Ordinary Income and Net Income are considered to broadly reflect the profitability of the core business. Meanwhile, the effective tax rate rose to 30.5% from 26.3% in the previous year, and the increased tax burden further pressured Net Income. Comprehensive income of ¥0.419B was slightly below Net Income of ¥0.445B, with other comprehensive income items unrelated to the core business, such as adjustments related to retirement benefits of △¥0.016B and valuation differences on securities of △¥0.010B, contributing to the divergence.
Earnings Forecasts and Guidance
Q1 progress against the full-year forecast was 25.5% for Revenue, at ¥10.73B / ¥42.00B; 21.7% for Operating Income, at ¥0.667B / ¥3.07B; 22.1% for Ordinary Income, at ¥0.640B / ¥2.90B; and 21.5% for Net Income, at ¥0.445B / ¥2.07B. While Revenue was progressing broadly in line with the standard quarterly progress rate of 25%, Operating Income, Ordinary Income, and Net Income were 3–4pt below the standard progress rate. As of the current quarter, there have been no revisions to the earnings or dividend forecasts, and the full-year plan remains unchanged.
Shareholder Returns
The full-year dividend forecast is ¥29.00, unchanged from the previous year's actual dividend of ¥29. Using the weighted-average number of shares outstanding during the period of 32.966 million shares, the annual dividend total is calculated at approximately ¥0.956B, resulting in a Payout Ratio of approximately 46.2% against the full-year Net Income forecast of ¥2.07B. No share repurchases have been confirmed, and shareholder returns are evaluated solely on the basis of dividends. Given the level of cash and deposits at ¥9.89B, the delay in profit progress during the current period is not considered to immediately constrain the continuation of dividend payments.
Risk Factors
-
Risk of gross profit margin deterioration: The gross profit margin was 38.0%, down 2.2pt from 40.2% in the previous year. If this declining trend continues, it could become a factor preventing the Company from achieving its full-year profit plan.
-
Delayed full-year progress: Progress rates for Operating Income, Ordinary Income, and Net Income were all 21–22%, below the standard quarterly progress rate of 25%. The extent of recovery in the second half will be a key point to monitor.
-
Increase in non-operating expenses: Interest expenses increased from ¥0.004B in the previous year to ¥0.019B, and non-operating income and expenses shifted from net income to net expenses. The increase in interest burdens is weighing on Ordinary Income.
Industry Benchmark (For Reference; Compiled by the Company)
Profitability and Returns
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Operating Income Margin | 6.2% | 17.5% (6.9%–23.1%) | −11.3pt |
| Net Income Margin | 4.1% | 8.9% (2.5%–15.6%) | −4.7pt |
The Company's Operating Income margin and Net Income margin are both substantially below the industry median, placing the Company at a lower level within the industry.
Growth and Capital Efficiency
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Revenue Growth Rate (YoY) | 5.2% | 9.8% (2.9%–13.0%) | −4.7pt |
Although the Revenue growth rate is below the industry median, it exceeds the lower bound of the IQR (2.9%), placing it at a below-median level within the industry.
※Source: Compiled by the Company
Key Points from the Earnings Results
-
Despite higher revenue, Operating Income declined because the gross profit margin fell by 2.2pt. The future trend in the gross profit margin will be a key focus as an inflection point in profitability.
-
Full-year progress was broadly in line with plan for Revenue at 25.5%, while profit progress was slightly behind at 21–22%. The extent of the recovery in profitability during the second half will be a key point to monitor.
-
Financial soundness remains strong, with an Equity Ratio of 70.3% and interest coverage of 35.1x, providing a foundation to support the continuation of shareholder returns at a Payout Ratio of approximately 46%.
Theoretical Share Price (Reference Value)
This is a mechanically calculated reference range based solely on publicly disclosed data using a residual income model (Ohlson-type model with an explicit 5-year fade). It is not a forecast of the market share price or a recommendation to take any specific investment action.
| Scenario | Theoretical Share Price |
|---|---|
| bear | ¥1,127 |
| base | ¥1,156 |
| bull | ¥1,170 |
| Assumptions | Value |
|---|---|
| Book Value per Share (BPS) | ¥1,317 |
| Adjusted Forecast EPS | ¥68.1 |
| Cost of Equity r | 9.65% (10-year government bond 2.65% + equity risk premium 6.00% + size premium 1.00%) |
| Residual Income Persistence Factor ω / Explicit Forecast Period | 0.62 / 5 years |
| Assumed Payout Ratio | 46.2% |
| Forecast EPS Confidence Adjustment | ×1.085 (based on the industry's historical guidance achievement rate) |
| Implied PBR / PER | 0.88x / 17.0x |
Sensitivity: ¥1,125–¥1,189 at ±1% for the cost of equity, and ¥1,151–¥1,160 at ±0.1 for ω.
Notes:
- Because forecast ROE is below the cost of equity, the theoretical value is below book value per share.
- Net assets as of the end of the quarter are used (there is a timing difference relative to the full-year forecast).
(Model used: Residual Income Model / Interest Rate Reference Month: 2026-06 / This value does not forecast or guarantee the future share price)
This report is an earnings analysis document automatically generated by AI through analysis of XBRL earnings summary data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting with professionals as necessary.
---End of Report---
AI Financial Analysis
Executive Summary
FY2027 Q1 was a mixed quarter: sales growth remained positive, but profitability deteriorated materially as cost growth outpaced revenue. Revenue increased 5.2% year on year to ¥10.728bn. Operating income declined 16.7% to ¥0.667bn despite the top-line expansion. Net income attributable to owners fell 25.8% to ¥0.445bn, equivalent to basic EPS of ¥13.52. Gross profit decreased 0.6% to ¥4.077bn as cost of sales rose 9.1% to ¥6.650bn. The gross margin contracted to 38.0% from 40.2% a year earlier, a decline of roughly 220bp. Operating margin compressed to 6.2% from 7.8%, or approximately 160bp. Net margin fell to 4.2% from 5.9%, a compression of around 170bp. SG&A expenses rose 2.4%, slower than revenue growth, and SG&A-to-sales therefore improved to 31.8% from 32.4%. The principal earnings pressure was consequently gross-margin erosion rather than excessive SG&A expansion. Ordinary income declined 21.3%, slightly faster than operating income, reflecting a less favorable non-operating balance. Interest expense rose to ¥0.019bn from ¥0.004bn, although interest coverage remained very strong at 35.1x. The annualized DuPont ROE was 4.1%, below the 8% threshold generally viewed as adequate, with the 4.2% net margin being the principal constraint. The balance sheet remains conservatively capitalized, with a 219.6% current ratio, 190.4% quick ratio, and 70.1% capital adequacy ratio. However, elevated receivable days, inventory days, and a 128-day cash conversion cycle warrant close monitoring because they increase working-capital intensity. Management retained its full-year forecast, implying that Q1 profit progress is modestly below the normal seasonal benchmark while revenue progress is broadly on track. The full-year outlook requires a meaningful recovery in gross margin and operating-profit conversion during the remaining quarters.
Profitability Analysis
Annualized ROE of 4.1% decomposes into a 4.2% net profit margin, 0.693x asset turnover, and 1.42x financial leverage. The low net margin is the main limiting factor in the DuPont structure; leverage is restrained and asset turnover is moderate for a diagnostics and reagent business with meaningful manufacturing assets. Revenue growth of 5.2% did not translate into earnings growth because cost of sales increased 9.1%, reducing gross profit by 0.6%. Gross margin declined approximately 220bp year on year to 38.0%, while operating margin fell about 160bp to 6.2%. SG&A increased only 2.4%, below sales growth, reducing the SG&A ratio by roughly 60bp to 31.8%; this indicates that operating leverage within overhead was favorable. The earnings miss was therefore centered on gross-profit conversion, potentially reflecting product mix, input costs, production utilization, or pricing, rather than a loss of SG&A discipline. EBIT margin was 6.2%, consistent with the reported operating margin. The tax burden was 0.695, slightly below the 0.70 reference level, while the 0.960 interest burden confirms that financing costs have only a limited effect on pre-tax profitability. Interest coverage of 35.1x further supports the conclusion that the Q1 earnings decline was operational rather than balance-sheet driven. The absence of extraordinary items means net income largely reflects recurring operating and non-operating performance. Sustainability of a recovery depends on restoring gross margin while retaining the observed SG&A efficiency.
Growth Assessment
The company operates solely in the diagnostics-reagent business, making consolidated sales growth directly representative of its core business. Q1 revenue of ¥10.728bn represents 25.5% of the full-year sales forecast of ¥42.0bn, broadly consistent with the standard 25% first-quarter progress rate. Full-year guidance calls for only 0.2% sales growth, implying that management expects a substantially slower growth rate after the first quarter. Q1 operating income of ¥0.667bn represents 21.7% of the ¥3.070bn full-year forecast, 3.3 percentage points below the standard 25% pace. Q1 net income of ¥0.445bn represents 21.5% of the ¥2.070bn full-year forecast, similarly below the normal first-quarter run rate. The retained forecast implies that margin recovery, rather than revenue acceleration, is the key earnings requirement for the balance of the year. Full-year guidance anticipates operating-income growth of 5.2% and ordinary-income growth of 2.0%, in contrast to the Q1 declines of 16.7% and 21.3%, respectively. This creates a higher execution bar for cost of sales, pricing, product mix, and production efficiency over subsequent quarters. The Q1 sales result provides evidence of underlying demand resilience, but the divergence between revenue and profit means the quality of growth has weakened. The diagnostics industry also faces reimbursement and pricing pressure, procurement-cost volatility, and demand variability for testing products, all of which can affect gross-margin normalization.
Financial Health
Liquidity is strong. Current assets of ¥31.699bn covered current liabilities of ¥14.438bn, producing a 219.6% current ratio and ¥17.261bn of working capital. The 190.4% quick ratio indicates that short-term obligations can be met without relying on inventory liquidation. Cash and deposits were ¥9.888bn, while trade receivables were ¥10.353bn and electronically recorded monetary claims were ¥2.120bn. Current liabilities include ¥3.000bn of current bonds and ¥0.300bn of current long-term loans; these short-term interest-bearing obligations are covered by cash alone and more than fully covered by liquid current assets. Long-term loans were ¥2.575bn, and reported debt-to-equity was 0.42x, below the 2.0x level associated with aggressive leverage. Debt-to-capital was 5.6%, indicating limited dependence on debt financing. Total equity of ¥43.497bn represented 70.3% of total assets, providing a substantial loss-absorption buffer. Interest coverage of 35.1x indicates ample capacity to service interest costs. Property, plant and equipment accounted for 36.9% of total assets, consistent with a manufacturing-oriented diagnostics platform. Asset retirement obligations were ¥0.065bn and do not appear material relative to equity or total assets.
Notable B/S Changes
Electronically recorded monetary claims: +¥0.975bn (+73.1%) year on year to ¥2.120bn - a substantial increase in receivables-related working capital that is consistent with the elevated 88-day DSO alert. Cash and deposits: -¥1.055bn (-9.6%) year on year to ¥9.888bn - liquidity remains ample, but the decline should be assessed alongside higher receivables-related balances and the extended cash conversion cycle. Construction in progress: -¥0.541bn (-70.5%) year on year to ¥0.226bn - suggests completion or transfer of ongoing capital projects, reducing the outstanding construction commitment balance. Retained earnings: -¥0.510bn (-1.7%) year on year to ¥30.374bn - reflects distributions and the lower current-period earnings contribution, though the retained earnings base remains substantial.
Cash Flow Quality
Dividend Sustainability
The full-year dividend forecast is ¥58 per share, unchanged from the disclosed forecast. Against forecast EPS of ¥62.79, the implied dividend payout ratio is approximately 92.4%. This is materially above the 60% level generally associated with a conservative dividend payout policy, leaving a narrow earnings retention buffer. Q1 EPS was ¥13.52, representing 21.5% of full-year forecast EPS, so delivery of the planned dividend relies on the anticipated earnings recovery in subsequent quarters. The strong liquidity position, low debt-to-capital ratio, and substantial equity base support financial flexibility. Nonetheless, the high forecast payout ratio means dividend sustainability is more sensitive to any shortfall in the company’s gross-margin recovery or full-year earnings plan. No share repurchase information is reflected in the provided figures; accordingly, the analysis refers to the dividend payout ratio rather than a total return ratio.
Risk Assessment
Business risks include Gross-margin risk: cost of sales rose 9.1% versus 5.2% sales growth, causing gross margin to decline roughly 220bp to 38.0%. Continued adverse product mix, procurement costs, pricing pressure, or lower production efficiency would jeopardize the forecasted full-year profit recovery., Diagnostics-market risk: as a single-segment diagnostics-reagent business, the company has limited segment diversification against changes in testing volumes, healthcare reimbursement, competitive tendering, and customer purchasing patterns., Receivables collection risk: DSO was 88 days, above the 60-day alert threshold. This ties up capital in customer balances and could pressure liquidity conversion if collection timing deteriorates., Inventory management risk: DIO was 112 days, above the 90-day alert threshold. For a diagnostics manufacturer, elevated inventory can raise obsolescence, expiry, demand-forecasting, and write-down risk..
Financial risks include Working-capital intensity: the 128-day cash conversion cycle exceeds the 120-day alert threshold. The combination of elevated receivable days and inventory days can increase financing needs even though reported liquidity is currently strong., Dividend coverage risk: the forecast dividend payout ratio is approximately 92.4%, limiting the earnings cushion should full-year EPS fall below plan., Short-term refinancing exposure is limited but present: ¥3.000bn of current bonds and ¥0.300bn of current long-term loans are included in current liabilities. Cash of ¥9.888bn and a 219.6% current ratio provide substantial coverage..
Key concerns include High receivable days are concerning because 88 days exceeds the 60-day alert level; the effect is slower conversion of recognized sales into cash and greater sensitivity to customer-payment timing., High inventory days are concerning because 112 days exceeds the 90-day alert level; the effect is increased capital lock-up and potential inventory-ageing exposure in reagent products., The long 128-day cash conversion cycle is concerning because it compounds collection and inventory risks; while the balance sheet can absorb it currently, it reduces cash-flow resilience if profitability weakens., Operating-profit progress of 21.7% versus a standard 25% Q1 pace means the unchanged full-year operating-income forecast requires improved profitability in later quarters..
Investment Implications
Key takeaways include Revenue growth was positive at 5.2%, but Q1 operating income and net income declined 16.7% and 25.8%, respectively., Margin deterioration was concentrated in cost of sales: gross margin fell about 220bp to 38.0%, while SG&A discipline improved the SG&A ratio by about 60bp., The company has a strong liquidity and solvency profile, including a 219.6% current ratio, 190.4% quick ratio, 70.1% capital adequacy ratio, and 35.1x interest coverage., The unchanged annual plan requires a material reversal from Q1 profit declines to full-year operating-income growth of 5.2%., The forecast payout ratio of approximately 92.4% elevates sensitivity of shareholder distributions to execution against the earnings plan..
Metrics to watch include Gross margin and cost-of-sales growth relative to revenue growth, Operating-margin recovery toward the full-year forecast trajectory, DSO of 88 days and the collection trend in trade and electronic receivables, DIO of 112 days, inventory ageing, and inventory write-downs, Cash conversion cycle relative to the current 128 days, Quarterly operating-income progress against the ¥3.070bn full-year forecast, EPS delivery versus the ¥62.79 full-year forecast supporting the ¥58 dividend.
Regarding relative positioning, The company’s balance sheet is more conservative than its current earnings profile: liquidity, capital adequacy, debt burden, and interest coverage are strong, while the annualized 4.1% ROE and 6.2% operating margin remain below the profitability levels typically associated with high-quality healthcare and diagnostics operators. Near-term relative positioning will depend primarily on whether gross-margin recovery validates management’s unchanged full-year earnings plan.